Selvigaltin (GB1211), an orally available small molecule galectin-three inhibitor designed as a cure for liver fibrosis and cirrhosis, was evaluated to evaluate the impact of hepatic impairment on its pharmacokinetics and safety to handle regulatory requirements. Members have been also excluded if they'd clinically important abnormalities in electrocardiogram (ECG) results https://edwinhawph.myparisblog.com/39828037/selvigaltin-an-overview